PLUS THERAPEUTICS, INC.
PSTVNasdaq
$3.74
↓ -4.1%Jul 17 close · end-of-day
Price
1Y↓ -53.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$24.9M
Enterprise Value
$9.7M
P/E
0.1
P/S
4.8
P/B
2.1
EV/EBITDA
—
PEG
—
FCF Yield
-87.4%
Dividend Yield
—
Revenue (TTM)
$5.2M
Net Income (TTM)
-$11.9M
Free Cash Flow (TTM)
-$21.7M
Gross Margin
—
Operating Margin
-364.4%
Net Margin
-230.2%
ROE
-99.8%
ROIC
—
Debt / Equity
—
Net Cash
$15.1M
Return 1Y
-60.9%
Company profile
Plus Therapeutics, Inc. focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma.
- CEO
- Marc H. Hedrick
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 20
- Headquarters
- Texas
- Website
- plustherapeutics.com
Management & directors
- Hedrick Marc HChief Executive Officer
- Sims Andrew John Hugh MacintyreChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
PSTV Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.0M↓ -2.9%
Diluted EPS-$1.05↓ -96.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $4.9M | $5.8M | $5.2M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.6M | -$12.5M | -$19.7M | -$13.3M | -$14.7M | -$15.3M |
| Net income | -$8.2M | -$13.4M | -$20.3M | -$13.3M | -$13.0M | -$22.4M |
| Diluted EPS | — | -$1.11 | -$11.58 | -$4.24 | -$2.34 | -$0.29 |
| Operating cash flow | -$8.4M | -$10.3M | -$13.0M | -$12.9M | -$10.6M | -$20.8M |
| Free cash flow | — | — | — | -$13.0M | -$10.7M | -$20.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | -271.1% | -252.3% | -293.5% |
| Net margin | — | — | — | -271.0% | -222.8% | -429.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $1.5M | $1.4M | $1.1M | $1.4M | $1.4M | $1.4M | $1.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.7M | -$3.8M | -$3.9M | -$3.5M | -$1.5M | -$4.5M | -$5.7M | -$7.1M |
| Net income | -$2.9M | -$2.9M | -$3.9M | -$17.4M | $5.2M | -$4.4M | -$5.7M | -$6.9M |
| Diluted EPS | -$0.71 | -$0.37 | -$0.51 | -$29.86 | -$0.01 | -$0.04 | $29.62 | -$1.05 |
| Operating cash flow | -$1.1M | -$3.7M | -$1.2M | -$6.2M | -$5.8M | -$2.5M | -$6.3M | -$6.2M |
| Free cash flow | -$1.2M | -$3.7M | -$1.2M | -$6.2M | -$5.8M | -$2.6M | -$6.3M | -$7.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -289.1% | -260.9% | -276.2% | -333.9% | -110.6% | -320.8% | -420.0% | -692.5% |
| Net margin | -229.9% | -197.4% | -276.4% | -1643.2% | 370.6% | -316.6% | -417.9% | -675.7% |
Company news
Jun 30, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Guse Kyle | Option exercise | 922 | $0.00 | $0.00 | filing |
| 2026-07-01 | ANDREWS RONALD ASBURY | Option exercise | 922 | $0.00 | $0.00 | filing |
| 2026-07-01 | van Es-Johansson An | Option exercise | 922 | $0.00 | $0.00 | filing |
| 2026-07-01 | HEDRICK MARC H· Chief Executive Officer | Option exercise | 6,387 | $0.00 | $0.00 | filing |
| 2026-07-01 | HEDRICK MARC H· Chief Executive Officer | Option exercise | 8,066 | $0.00 | $0.00 | filing |
| 2026-07-01 | HEDRICK MARC H· Chief Executive Officer | Option exercise | 1,986 | $0.00 | $0.00 | filing |
| 2026-07-01 | Clowes Howard | Option exercise | 922 | $0.00 | $0.00 | filing |
| 2026-07-01 | Hawkins Richard J | Option exercise | 922 | $0.00 | $0.00 | filing |
| 2026-07-01 | Sims Andrew John Hugh MacIntyre· Chief Financial Officer | Option exercise | 1,533 | $0.00 | $0.00 | filing |
| 2026-07-01 | Sims Andrew John Hugh MacIntyre· Chief Financial Officer | Option exercise | 1,165 | $0.00 | $0.00 | filing |
| 2026-07-01 | Sims Andrew John Hugh MacIntyre· Chief Financial Officer | Option exercise | 287 | $0.00 | $0.00 | filing |
| 2026-04-01 | Sims Andrew John Hugh MacIntyre· Chief Financial Officer | Option exercise | 38,323 | $0.00 | $0.00 | filing |
| 2026-04-01 | Sims Andrew John Hugh MacIntyre· Chief Financial Officer | Option exercise | 29,129 | $0.00 | $0.00 | filing |
| 2026-04-01 | HEDRICK MARC H· Chief Executive Officer | Option exercise | 159,681 | $0.00 | $0.00 | filing |
| 2026-04-01 | HEDRICK MARC H· Chief Executive Officer | Option exercise | 201,632 | $0.00 | $0.00 | filing |
| 2026-01-01 | HEDRICK MARC H· Chief Executive Officer | Option exercise | 159,681 | $0.00 | $0.00 | filing |
| 2026-01-01 | Sims Andrew John Hugh MacIntyre· Chief Financial Officer | Option exercise | 38,323 | $0.00 | $0.00 | filing |
| 2025-11-04 | Sims Andrew John Hugh MacIntyre· Chief Financial Officer | Buy | 20,000 | $0.51 | $10,200.00 | filing |
| 2025-10-01 | HEDRICK MARC H· Chief Executive Officer | Option exercise | 159,681 | $0.00 | $0.00 | filing |
| 2025-10-01 | Sims Andrew John Hugh MacIntyre· Chief Financial Officer | Option exercise | 38,323 | $0.00 | $0.00 | filing |
| 2025-08-22 | Lenk Robert P | Buy | 110,000 | $0.49 | $53,779.00 | filing |
Latest 21 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.